A multicentre phase II study of AZD1775 plus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

Multicentre Phase ◽

Peritoneal Cancer ◽

840P Famitinib malate plus camrelizumab for recurrent platinum-resistant ovarian/fallopian tube/primary peritoneal cancer and advanced cervical cancer: An open-label, multicenter phase II study

Annals of Oncology ◽

10.1016/j.annonc.2020.08.979 ◽

2020 ◽

Vol 31 ◽

pp. S630

Author(s):

L. Xia ◽

Q. Zhou ◽

Y. Zhang ◽

Y. Gao ◽

W. Hu ◽

...

Keyword(s):

Cervical Cancer ◽

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Advanced Cervical Cancer ◽

Open Label ◽

Peritoneal Cancer ◽

Multicenter Phase ◽

Pharmacodynamic biomarkers from phase II study of the SMAC (Second Mitochondrial-Derived Activator of Caspases)-mimetic birinapant (TL32711; NSC 756502) in relapsed platinum-resistant epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC) (NCT01681368).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.5585 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 5585-5585 ◽

Cited By ~ 2

Author(s):

Kristen Paige Bunch ◽

Anne M. Noonan ◽

Jung-min Lee ◽

Ciara Catherine Maria O'Sullivan ◽

Nicole D. Houston ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Fallopian Tube Cancer ◽

Peritoneal Cancer ◽

Platinum Resistant ◽

Pharmacodynamic Biomarkers

Multicenter randomized Phase II study of AZD1775 plus chemotherapy versus chemotherapy alone in patients with platinum-resistant TP53-mutated epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.tps5608 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. TPS5608-TPS5608 ◽

Cited By ~ 1

Author(s):

Kathleen N. Moore ◽

D. Scott McMeekin ◽

Erika Paige Hamilton ◽

Donald K Strickland ◽

Suzanne Fields Jones ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Peritoneal Cancer ◽

Platinum Resistant ◽

Randomized Phase Ii

5002 ORAL Results from a Phase II randomized, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(07)71174-6 ◽

2007 ◽

Vol 5 (4) ◽

pp. 311-312

Author(s):

S. Makhija ◽

D. Glenn ◽

F. Ueland ◽

D. Dizon ◽

V. Paton ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Double Blind Trial ◽

Double Blind ◽

Peritoneal Cancer ◽

Blind Trial ◽

Phase II trial of weekly nab-paclitaxel with GM-CSF as an immune modulator in recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer: Clinical and immune responses.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.5580 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 5580-5580

Author(s):

John Ben Liao ◽

Ron E. Swensen ◽

Jessica Reichow ◽

Kelsie J Ovenell ◽

Jennifer Childs ◽

...

Keyword(s):

Immune Responses ◽

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Trial ◽

Peritoneal Cancer ◽

Immune Modulator ◽

Gm Csf ◽

A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group Study (GOG 146Q)

Yearbook of Oncology ◽

10.1016/j.yonc.2011.07.016 ◽

2011 ◽

Vol 2011 ◽

pp. 74-75

Author(s):

J.T. Thigpen

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Peritoneal Cancer ◽

Platinum Sensitive

A phase II study of GM-CSF and rIFN-γ1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2009.02.007 ◽

2009 ◽

Vol 113 (2) ◽

pp. 210-215 ◽

Cited By ~ 27

Author(s):

Kathleen M. Schmeler ◽

Saroj Vadhan-Raj ◽

Pedro T. Ramirez ◽

Sachin M. Apte ◽

Lorenzo Cohen ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Peritoneal Cancer ◽

Gm Csf ◽

Platinum Sensitive

A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.10.001 ◽

2018 ◽

Vol 151 (3) ◽

pp. 422-427 ◽

Cited By ~ 7

Author(s):

Bradley J. Monk ◽

James T. Kauderer ◽

Katherine M. Moxley ◽

Albert J. Bonebrake ◽

Summer B. Dewdney ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Gynecologic Oncology ◽

Weekly Paclitaxel ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Peritoneal Cancer ◽

Phase II study of pembrolizumab (pembro) combined with pegylated liposomal doxorubicin (PLD) for recurrent platinum-resistant ovarian, fallopian tube or peritoneal cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.04.059 ◽

2018 ◽

Vol 149 ◽

pp. 24 ◽

Cited By ~ 5

Author(s):

U.A. Matulonis ◽

W. Barry ◽

R.T. Penson ◽

P.A. Konstantinopoulos ◽

W. Luo ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Study ◽

Pegylated Liposomal Doxorubicin ◽

Peritoneal Cancer ◽

A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q)

Yearbook of Medicine ◽

10.1016/s0084-3873(11)00207-0 ◽

2011 ◽

Vol 2011 ◽

pp. 154-155

Author(s):

J.T. Thigpen

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Peritoneal Cancer ◽

Platinum Sensitive